In a significant development, Constructive Bio has successfully secured £43.4m in funding. This underscores the firm’s ambitious genomic synthesis initiatives.
- Founded in 2021, the startup is pioneering programmable molecule technology to bolster pharmaceutical and therapeutic solutions.
- The funding round was led by key investors including Ahren, OMX Ventures, and Paladin Capital Group, enhancing the firm’s financial standing.
- Constructive Bio is recognised for its unique ability to transform living cells into sustainable biofactories, a process helmed by founder Prof Jason Chin.
- The total financing to date, post this round, now stands at $75m, showcasing strong investor confidence.
Constructive Bio, a promising synthetic genomics startup based in Cambridge, has made a significant stride by securing £43.4m in the first close of its Series A funding round. This financing milestone, equivalent to $58m, highlights the company’s capability and future potential in the field of genomics.
Established in 2021, the innovative firm is at the forefront of developing programmable molecules. Through its advanced genomic synthesis process, Constructive Bio aims to facilitate the creation of molecules with novel properties and functions. These developments are expected to significantly enhance pharmaceutical and therapeutic treatment options.
The recent funding round was successfully led by a consortium of prominent investors, including Ahren, OMX Ventures, and Paladin Capital Group. This round brings the cumulative funding for Constructive Bio to an impressive $75m, marking a vote of confidence from the investment community.
The technology employed by Constructive Bio is described by its founder, Prof Jason Chin, as unparalleled. He states, “Constructive Bio is the only company that can turn living cells into sustainable biofactories in which we can programme the sequence, composition and chemistry of proteins, and new biopolymers.” This positions the firm uniquely in the biotechnology sector.
Paladin Capital’s managing director, Paul Conley, expressed his admiration for the company’s progress, stating that witnessing the evolution of Constructive Bio’s platform is remarkable. The investment is driven by the potential for groundbreaking advances in medicines, enzymes, and biomaterials supported by their bioengineering technologies.
Additional financial backing came from Fine Structure Ventures, +ND Capital, and individual investor Jonathan Milner, reflecting a broad spectrum of support from the investment sector. Previously, the company had raised £12.5m in a seed round in August 2022.
The successful capital raise solidifies Constructive Bio’s position as a frontrunner in synthetic genomics, poised to transform the biotechnology landscape.
